Heparin-induced thrombocytopenia: Difference between revisions
Jump to navigation
Jump to search
m (Protected "Heparin-induced thrombocytopenia": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))) |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 10: | Line 10: | ||
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}, [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto:psingh13579@gmail.com], Aric C. Hall, M.D., [mailto:achall@bidmc.harvard.edu] | {{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}, [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto:psingh13579@gmail.com], Aric C. Hall, M.D., [mailto:achall@bidmc.harvard.edu] | ||
==[[ | ==[[Aplastic anemia overview|Overview]]== | ||
==[[ | ==[[Aplastic anemia historical perspective|Historical Perspective]]== | ||
==[[Aplastic anemia classification|Classification]]== | |||
==[[Aplastic anemia pathophysiology|Pathophysiology]]== | |||
==[[Aplastic anemia causes|Causes]]== | |||
==[[Aplastic anemia differential diagnosis|Differentiating Aplastic anemia from other Diseases]]== | |||
==[[Aplastic anemia epidemiology and demographics|Epidemiology and Demographics]]== | |||
==[[Aplastic anemia risk factors|Risk Factors]]== | |||
==[[Aplastic anemia screening|Screening]]== | |||
==[[Aplastic_anemia_natural_history,_complications_and_prognosis|Natural History, Complications, and Prognosis]]== | |||
==Diagnosis== | ==Diagnosis== | ||
[[Aplastic anemia history and symptoms|History and Symptoms]] | [[Aplastic anemia physical examination|Physical Examination]] | [[Aplastic anemia laboratory findings|Laboratory Findings]] | [[Aplastic anemia electrocardiogram|Electrocardiogram]] | [[Aplastic anemia chest x ray|Chest X Ray]] | [[Aplastic anemia CT|CT]] | [[Aplastic anemia MRI|MRI]] | [[Aplastic anemia echocardiography or ultrasound|Echocardiography or Ultrasound]] | [[Aplastic anemia other imaging findings|Other Imaging Findings]] | [[Aplastic anemia other diagnostic studies|Other Diagnostic Studies]] | |||
==Treatment== | ==Treatment== | ||
[[Aplastic anemia medical therapy|Medical Therapy]] | [[Aplastic anemia surgery|Surgery]] | [[Aplastic anemia primary prevention|Primary Prevention]] | [[Aplastic anemia secondary prevention|Secondary Prevention]] | [[Aplastic anemia cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Aplastic anemia future or investigational therapies|Future or Investigational Therapies]] | |||
==Case Studies== | |||
[[Aplastic anemia case study one|Case #1]] | |||
==See also== | ==See also== | ||
[[Heparin]] | * [[Heparin]] | ||
* [[Heparin-associated thrombocytopenia]] | |||
[[Heparin-associated thrombocytopenia]] | * [[Heparin-binding EGF-like growth factor]] | ||
[[Heparin-binding EGF-like growth factor]] | |||
==Reference== | ==Reference== | ||
| Line 36: | Line 48: | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
Revision as of 21:40, 2 June 2016
 |
Resident Survival Guide |
|
Heparin-induced thrombocytopenia |
|
Differentiating Heparin-induced thrombocytopenia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Heparin-induced thrombocytopenia On the Web |
|
American Roentgen Ray Society Images of Heparin-induced thrombocytopenia |
|
Directions to Hospitals Treating Heparin-induced thrombocytopenia |
|
Risk calculators and risk factors for Heparin-induced thrombocytopenia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Priyamvada Singh, M.B.B.S. [3], Aric C. Hall, M.D., [4]
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Aplastic anemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies